drugset / Trial / NCT06677710
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Outcome
Outcome not reported
Stopped (Business): “Business Reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDP-023 | Cell therapy | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Ocrelizumab | Monoclonal antibody | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |